Merck (NYSE:MRK) announced on Friday that an expert panel of the EU drug regulator, the European Medicines Agency (EMA) endorsed an injectable version of its blockbuster cancer therapy Keytruda (pembrolizumab). The New Jersey-based pharma giant said that EMA’s Committee for ...